BACKGROUND: @entity2067 antagonist oral anticoagulants (VKA-OACs) are effective for primary and secondary prevention of @entity887 . The rate of haemorrhagic @entity16 in @entity1 admitted to neurology departments in Spain is not yet known. AIMS: We aimed to determine the clinical and epidemiological characteristics of @entity1 with @entity932 secondary to VKA-OACs as well as the incidence of this severe complication. METHODS: We conducted a retrospective, descriptive, multi-centre study using information from the medical records of all @entity1 admitted to neurology departments, diagnosed with spontaneous @entity932 , and treated with VKA-OACs within a 1-year period. We collected demographic and care data from centres, @entity1 ' medical records [demographic data, medical history, @entity548 origin, vascular risk factors, concomitant treatment, and National Institutes of Health @entity64 Scale (NIHSS) scores], and @entity1 ' outcome at 3 months [independence (modified Rankin Scale score <3) and mortality rate]. RESULTS: Twenty-one hospitals serving a population of 8,155,628 inhabitants participated in the study. The total number of cases was 235, the mean age was 78.2 (SD 9.4) years, and the baseline NIHSS score was 11.6 (SD 9.5; median 9; interquartile range 14). The VKA-OACs used were @entity11271 in 95.3% (224 @entity1 ) and @entity1229 in 4.7% (11 @entity1 ). The @entity548 origin was deep in 29.8%, lobar in 25.5%, intraventricular in 11.5%, extensive in 17.4% (>100 ml), cerebellar in 12.3%, and in the brainstem in 3.4%. The international normalised ratio was within therapeutic ranges at admission (according to indication) in 29.4% (69 @entity1 ). The global incidence (cases per 100,000 inhabitants per year) is 2.88. The in-hospital mortality rate was 40%, and 24.3% of the @entity1 were independent at 3 months, while the mortality at 3 months was 42.6%. CONCLUSION: VKA-OAC treatment is associated with a large percentage of all cases of spontaneous @entity932 , an event leading to high dependence and mortality rates.

Epidemiology of Intracranial @entity548 Associated with XXXX Antagonist Oral Anticoagulants in Spain: TAC Registry.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial haemorrhage'] @entity64 :: ('MESH:D020521', 'Disease') :: ['Stroke'] @entity11271 :: ('MESH:D000074', 'Chemical') :: ['acenocoumarol'] @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhage'] @entity2067 :: ('MESH:D014812', 'Chemical') :: ['Vitamin K'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological complications'] @entity887 :: ('MESH:D004617', 'Disease') :: ['embolic events'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']
@entity2067 :: (MESH:D014812,Chemical) :: ['Vitamin K']
